Developing strategies for psychopharmacological studies in preschool children

Laurence L Greenhill1, Peter S Jensen, Howard Abikoff

  • 1New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY 10032, USA. LarryLGreenhill@cs.com.

Insights

Conducting psychopharmacology studies in preschoolers faces significant ethical, practical, and regulatory hurdles. Addressing these challenges is crucial for ensuring medication safety and efficacy in young children.

Area of Science:

  • Pediatric psychopharmacology research.
  • Child and adolescent psychiatry.
  • Developmental psychology.

Background:

  • Preschoolers are increasingly prescribed psychopharmacological agents.
  • Limited research exists on the safety and efficacy of these medications in young children.
  • Significant obstacles hinder psychopharmacological studies in this population.

Framework:

  • Key domains identified include diagnosis, assessment, ethics, research design, and regulatory issues.
  • A Pediatric Psychopharmacology Initiative is recommended to consolidate research efforts.
  • Expertise from developmental specialists is vital for robust study design.

Implementation:

  • Interactive workshops highlighted practical and ethical challenges.
  • Recommendations include developing scholarly reviews and guides for institutional review boards.
  • "N of 1" case studies can offer valuable clinical insights.
  • Eligibility criteria should focus on preschoolers with severe, contextually relevant symptoms.

Implications:

  • The development of practice parameters for preschooler psychopharmacology is essential.
  • Regulatory activities should consider symptom complexes, not just diagnoses.
  • Further research is imperative to establish evidence-based treatment guidelines for young children.
Abstract

Related Concept Videos

Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...